Acquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention - Seite 2

medical team during and after therapy. This is accomplished via a user-friendly
app that captures the experience and symptoms of patients through basic
health-related questions. The patient-reported information allows caregivers to
assess the effectiveness of treatments promptly, to detect and treat health
issues early and to adapt the treatment regimen immediately if necessary and can
in addition be used to improve clinical study experience. Research shows that
digital monitoring can have a beneficial effect on patient health comparable to
that of a new medication, revealing the potential impact of this affordable,
easy-to-use technology.

"Personalized digital health intervention to every cancer patient - this has
been our vision from the very beginning. Measuring what matters to patients is
paramount for value-based healthcare," expressed Lauri Sippola, CEO of Kaiku
Health . "We are grateful for Debiopharm's active support in developing our
digital therapeutics pipeline as our Series A lead investor in 2018. We are
encouraged that through this acquisition by Elekta, that now even more patients
can have the possibility to receive more personalized cancer care through Kaiku
technology."

Recently, Kaiku Health's interventions have also been implemented to support the
efficient monitoring of COVID-19 patients, including a specific symptom
monitoring module in co-operation with the leading Swiss university hospital
group, the Geneva University Hospitals (HUG).

About Kaiku Health

Kaiku Health is a Class 1 Medical Device in cancer care, providing digital
health interventions based on patient-reported outcomes. Kaiku Health has
modules for over 25 cancer types across different cancer care pathways. It is
currently in use in over 40 European cancer clinics and hospitals. For more
information, please visit http://www.kaikuhealth.com and connect with us at
Twitter @KaikuHealth.

About Elekta

For almost five decades, Elekta has been a leader in precision radiation
medicine. Our more than 4,000 employees worldwide are committed to ensuring
everyone in the world with cancer has access to - and benefits from - more
precise, personalized radiotherapy treatments. Headquartered in Stockholm,
Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit
http://www.elekta.com/ or follow @Elekta (https://twitter.com/Elekta) on
Twitter.

About Debiopharm

Debiopharm develops, manufactures and invests in innovative therapies and
technologies that respond to high unmet medical needs in oncology and bacterial
infections. We aim to provide strategic funding and guidance for companies with
Smart Data & Digital Health solutions with the ambition to change the way drugs
are developed and the way patients are treated. Our growing portfolio company
achievements includes 18 FDA clearances or CE marks and 2 IPOs. Since 2008, the
company has invested nearly USD 100 millions and led 10 out of the 14 last
investment rounds in its portfolio companies.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews and @debiopharmfund

Pressekontakt:

Debiopharm Contact:

Dawn Haughton - Communication Manager
[e-mail]
Tel: [phone]

Additional content: https://www.presseportal.de/pm/121610/4605974
OTS: Debiopharm International SA